US Stock Market Closed

Dashboard

Outlook Therapeutics, Inc. (OTLK)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity

B

Analyst Opinion

B

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

About

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Cranbury, NJ.

CEO

Lawrence A. Kenyon

Employees

14

Industry

Ophthalmology Biopharmaceuticals

Sector

Healthcare

Headquarters

Cranbury

Exchange

NASDAQ

Summary Stats

Market Cap

265M

Revenue

5.85M

Net Income

-49.2M

EPS

-$1.00

Price-to-Earnings

-1.17

Price-to-Book

24.13

Debt-to-Equity

1.76

News

Analyst Ratings

Price targets projected by 5 analysts

High

$8.00

Average

$5.25

Low

$3.00

Ratings calculated by 5 analysts

Buy

5

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Not Available

Actual

-$0.08 -

Consensus

-

Report Date

Year Ago

-0.07

Year Ago Change %

Down 14%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites